Back to results
US 2024/0391998 A1Published application
Engineered chimeric fusion protein compositions and methods of use thereof
AssigneeMyeloid Therapeutics, Inc.
InventorsDaniel Getts, Yuxiao Wang
Life of this patent
Estimating the term…
Abstract
Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
Claims20
A composition comprising a recombinant polynucleic acid, wherein the recombinant polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:
- (a) an extracellular domain comprising an anti-GPC3 binding domain,
- wherein the anti-GPC3 binding domain comprises:
- a heavy chain comprising a heavy chain variable domain, the heavy chain variable domain comprising a heavy chain complementarity determining region 1 (HC CDR1) sequence of DYEMH (amino acid residues 31-35 of SEQ ID NO:
- 97), a HC CDR2 sequence of ALDPKTGDTAYSQKFKG (amino acid residues 50-66 of SEQ ID NO:
- 97), and a HC CDR3 sequence of FYSYTY (amino acid residues 99-104 of SEQ ID NO:
- 97), and
- a light chain comprising a light chain variable domain, the light chain variable domain comprising a light chain complementarity determining region 1 (LC CDR1) sequence of RSSQSLVHSNRNTYLH (amino acid residues 24-39 of SEQ ID NO:
- 98), a LC CDR2 sequence of KVSNRFS (amino acid residues 55-61 of SEQ ID NO:
- 98), and a LC CDR3 sequence of SQNTHVPPT (amino acid residues 94-102 of SEQ ID NO:
- 98);
- and
- (b) a transmembrane domain operatively linked to the extracellular domain, wherein the transmembrane domain comprises a transmembrane domain from CD16a, CD64, CD68 or CD89.
9 more elements
A composition comprising a recombinant mRNA, wherein the recombinant mRNA comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:
- (I) an extracellular domain comprising (a) an anti-GPC3 binding domain, wherein the anti-GPC3 binding domain comprises a sequence of SEQ ID NO:
- 106, and (b) an extracellular domain from CD89;
- (II) a transmembrane domain from CD89;
- and
- (III) an intracellular domain comprising an intracellular signaling domain from CD89;
- wherein the composition is encapsulated by a lipid nanoparticle.
3 more elements
Dependencies are inferred from the claim text.